Hubei Daily Reports: MiaoLingBio Builds One of China’s Largest In-Stock Plasmid Libraries, Helping R
Hubei Daily Reports: MiaoLingBio Builds One of China’s Largest In-Stock Plasmid Libraries, Helping Researchers Avoid Delays
In April 2026, Hubei Daily published a special report on Wuhan MiaoLing Bio Technology Co., Ltd., focusing on the company’s industry-leading library of more than 100,000 in-stock plasmids, proprietary magnetic bead-based purification technology, industrial applications of plasmid technology, and global expansion strategy.
The report highlighted MiaoLingBio’s technological innovation and industry value in providing foundational tools for genetic research.
The Full Report Is Reproduced Below:
Hubei Daily All-Media Reporter Yanfangting Yan
Correspondents Qiong Wang, Yaolin Tian, and Mengying Li
From tackling difficult diseases to transforming quality of life, gene therapy is bringing unprecedented changes to human health.
Last year, China’s first domestically developed gene therapy for hemophilia B, “Xinjiuning,” was approved through the priority review pathway, providing a new treatment option for adult patients with moderate to severe hemophilia B.
The starting point for the development of these life-saving therapies is often a tiny DNA molecule invisible to the naked eye: the plasmid.
In Wuhan’s Optics Valley Biocity, MiaoLingBio, a company with more than a decade of experience in the plasmid industry, has built one of China’s largest in-stock plasmid libraries. With more than 100,000 genetic vectors, the company has become an important behind-the-scenes enabler for numerous research teams working to advance gene therapy from early-stage research to practical applications.
A 150,000+ In-Stock Genetic Vector Library Means Researchers No Longer Have to “Wait for Materials”
Walking into MiaoLingBio’s laboratory, visitors can see rows of freezers operating at −20°C, storing more than 100,000 different plasmid products.
These tiny DNA molecules, invisible to the naked eye, are essential tools for cutting-edge research in gene therapy, cell therapy, and other areas of the life sciences.
“Plasmids are like a fleet of specially designed ‘ferries’ that precisely deliver the genes researchers need to modify or supplement into cells,” explained Dr. Zifeng Zheng, Head of Research at MiaoLingBio.
MiaoLingBio’s role is essentially to “build the ferries in advance.”
The company’s founding team entered the field as early as 2014 and has since established one of China’s leading in-stock plasmid libraries. The collection covers genetic research needs across multiple species, including humans, mice, and pigs.
Universities, hospitals, and research institutions can simply search for a gene identifier on the company’s website and place an order as conveniently as they would when shopping online. This enables researchers to obtain plasmids when they need them and immediately proceed with experiments, significantly shortening the preparation stage of research.
Proprietary Magnetic Bead Purification Technology Saves Researchers Up to One Month of Repetitive Work
Plasmids are propagated in Escherichia coli, and the downstream extraction process plays a critical role in determining the quality and usability of the final product.
Traditional methods rely heavily on manual operations and often suffer from low efficiency as well as challenges in controlling impurities and endotoxin levels.
“Endotoxins are contaminants associated with E. coli. If they are not adequately removed, they can affect the reliability of experimental results,” Dr. Zheng explained.
To address this challenge, MiaoLingBio’s R&D team spent nearly two years developing proprietary plasmid extraction reagents and supporting magnetic beads. The company also customized domestically manufactured automated extraction equipment.
MiaoLingBio has also expanded the application of its plasmid-related biotechnology into agriculture.
The company has established a 600-mu ecological orchard in Ezhou, Hubei Province. By applying plant virus-free tissue culture technology, the company aims to improve planting material quality at the source and reduce the incidence of pests and diseases, while following an ecological cultivation model without pesticides or chemical fertilizers.
In 2025, MiaoLingBio generated annual revenue of RMB 34 million, with annual growth remaining stable at approximately 30%–40%.
The company also operates a P2-level clean laboratory and provides high-standard lentiviral packaging services, further strengthening its capabilities across the plasmid and viral vector workflow.
MiaoLingBio’s products are currently exported to multiple countries, including the United States, Japan, India, Canada, and Vietnam.
To meet growing demand from the global scientific research community, the company has launched the construction of an expanded large-scale in-stock plasmid library. The project is designed to increase the production capacity of its existing collection of more than 100,000 plasmid types by 10-fold, providing faster and more scalable access to genetic research tools for scientists worldwide.
Original Report：
Publish Comment
Comment Record